SRGAP3 Antibody

Code CSB-PA022663GA01HU
Size $600
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
SRGAP3
Alternative Names
ARHGAP 14 antibody; ARHGAP14 antibody; Gbi antibody; ME GAP antibody; MEGAP antibody; Mental disorder associated GAP antibody; Mental disorder-associated GAP antibody; Rho GTPase activating protein 14 antibody; Rho GTPase-activating protein 14 antibody; SLIT ROBO Rho GTPase activating protein 3 antibody; SLIT-ROBO Rho GTPase-activating protein 3 antibody; srGAP 2 antibody; srGAP 3 antibody; srGAP2 antibody; srGAP3 antibody; SRGP 2 antibody; SRGP2 antibody; SRGP3_HUMAN antibody; WAVE associated Rac GTPase activating protein antibody; WAVE-associated Rac GTPase-activating protein antibody; WRP antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Human SRGAP3
Immunogen Species
Homo sapiens (Human)
Isotype
IgG
Purification Method
Antigen Affinity Purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
PBS with 0.02% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
Tested Applications
ELISA,WB,IHC
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
GTPase-activating protein for RAC1 and perhaps Cdc42, but not for RhoA small GTPase. May attenuate RAC1 signaling in neurons.
Gene References into Functions
  1. A single PXXP motif in the C-terminal region of srGAP3 mediates binding to multiple SH3 domains. PMID: 25819436
  2. Nuclear-localized srGAP3 interacts with Brg1. This interaction is mediated by the C-terminal of srGAP3 and the ATPase motif of Brg1. PMID: 24561795
  3. deletion of SRGAP3 provides the most convincing explanation for our patient's phenotype, and our observations lend further weight to a causative role of SRGAP3 haploinsufficiency in mental retardation. PMID: 24300292
  4. conclude that srGAP3 has tumor suppressor-like activity in HMECs, likely through its activity as a negative regulator of Rac1 PMID: 23108406
  5. putative role in severe mental retardation PMID: 12195014
  6. Data suggest that MEGAP negatively regulates cell migration by perturbing the actin and microtubule cytoskeleton and by hindering the formation of focal complexes. PMID: 16730001
  7. We found no association between SRGAP3/MEGAP haploinsufficiency and mental retardation. PMID: 19433673
  8. Current evidence suggests that SRGAP3 is the major determinant of mental retardation in distal 3p deletions. PMID: 19760623
  9. FNBP2, ARHGAP13, ARHGAP14 and ARHGAP4 constitute the FNBP2 family characterized by FCH, RhoGAP and SH3 domains. PMID: 12736724

Show More

Hide All

Involvement in disease
A chromosomal aberration involving SRGAP3 is found in a patient with severe idiopathic mental retardation (PubMed:12195014). Translocation t(X;3)(p11.2;p25) (PubMed:12195014).
Tissue Specificity
Highly expressed in adult and fetal brain. Expressed at low levels in kidney. Isoform 3 is expressed in the kidney but is absent in the brain.
Database Links

HGNC: 19744

OMIM: 606525

KEGG: hsa:9901

STRING: 9606.ENSP00000373347

UniGene: Hs.654743

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*